Objectives This study responds to a request in the National Institute for Health and Care
Excellence (NICE) guidance to assess the impact of using alternative sources of utility …

Objective: This review sought to gain a comprehensive, up-to-date understanding of the
epidemiology and cost and healthcare resource use (HCRU) burden of amyotrophic lateral …

Purpose The aim of this study was to evaluate the cost effectiveness of cladribine compared
with alemtuzumab, natalizumab, and ocrelizumab for the treatment of highly active multiple …

Background Decision-analytic models used in economic evaluations of disease-modifying
therapies for relapsing–remitting multiple sclerosis (RRMS) have characterized disease …

Background Selection of appropriate trial endpoints and outcome measures is particularly
important in rare disease and rapidly progressing disease such as amyotrophic lateral …

Background and aims Relapses are an important clinical feature of multiple sclerosis (MS)
that result in temporary negative changes in quality of life (QoL), measured by health state …

Background Motor neurone disease (MND) is a devastating condition which greatly
diminishes patients' quality of life and limits life expectancy. Health technology appraisals of …

Objective To assess the relationship among measurements of strength, function, and quality
of life in an amyotrophic lateral sclerosis (ALS) clinical trial. Methods In the FORTITUDE-ALS …

Background Multiple sclerosis (MS) is a chronic, autoimmune, and inflammatory disease.
The economic burden of MS is substantial, and the high cost of Disease-modifying drugs …

Objective: The aim of this study was to assess cost-effectiveness of the different Disease
Modifying Drugs (DMD) used as first-line treatments (interferons IM IFN β-1a, SC IFN β-1a …